Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas

Figures & data

Figure 1 Representative images of CD70 immunostaining in ovarian cancer tissues. (A) high CD70 expression; (B) low CD70 expression having <10% of tumor cells with strong staining intensity; (C) low CD70 expression with totally negative staining; (D) negative control (primary antibody was replaced by immunoglobulin G).

Table 1 Correlation between CD70 expression levels with clinicopathological characteristics in ovarian carcinomas

	Total	CD70 expression		P-value
		Low	High
Age
<51 years	36	30	6	0.883
≥51 years	56	46	10
Grade
G1	16	12	4
G2	32	26	6	0.572
G3	44	38	6
FIGO stage
3	67	52	15	0.060
4	25	24	1
Level of cytoreduction achieved
Optimal	45	38	7	0.649
Suboptimal	47	38	9
Response to cisplatin-based chemotherapy
Resistant	30	19	11	0.001
Sensitive	62	57	5

Abbreviation: FIGO, International Federation of Gynecology and Obstetrics.

Figure 2 Kaplan–Meier survival curves for overall survival rates of ovarian cancer patients according to CD70 expression.

Note: High CD70 expression subgroup showed a shorter overall survival than the low CD70 expression group (P = 0.012, log-rank test).
Abbreviation: n, number.

Table 2 Multivariate analysis of overall survival with regard to clinicopathological characteristics and CD70 expression

Characteristics	Multivariate analysis
	Hazard ratio (95% CI)	P-value
Age
(<51 years versus ≥ 51 years)	0.947 (0.498–1.801)	0.867
Grade
(grade 1 versus grade 2 versus grade 3)	1.155 (0.774–1.723)	0.480
FIGO stage
(3 versus 4)	1.226 (0.566–2.655)	0.606
Level of cytoreduction achieved (optimal versus suboptimal)	0.730 (0.405–1.316)	0.295
Response to cisplatin-based chemotherapy
(resistant versus sensitive)	2.164 (1.023–4.578)	0.043
Level of CD70 expression
(high versus low)	3.864 (1.703–8.766)	0.001

Abbreviations: CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics.